Novaliq Plans to File a Markting Authorisation Application for CyclASol® in the E.U. for the Treatment of Dry Eye Disease in July 2023
8.2.2023 16:00:00 EET | Business Wire | Press release
Novaliq, a biopharmaceutical company focusing on first- and best-in-class ocular therapeutics based on the unique EyeSol® water-free technology, today announced its plans for filing a Marketing Authorisation Application (MAA) for CyclASol® (ciclosporin ophthalmic solution), a first-of-its-kind anti-inflammatory product for the treatment of dry eye disease (DED) in the European Union.
The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) determined that CyclASol® is eligible to be reviewed in a centralized procedure to receive a Union Marketing Authorisation for the European Economic Area (EEA). In December 2022, EMA stated in its response that, based on the documentation provided by Novaliq, a submission is in the interest of patients at Community level under Article 3(2)b - Interest of patients of Regulation (EC) No 726/2004. Consequently, Novaliq has submitted a letter of intent to EMA to file the MAA in July 2023.
Dry eye is one of the most common ocular surface disorders with approximately 15 million diagnosed patients in the 5 largest European countries1. Treatment options for DED in the European market are limited, with only one approved drug therapy restricted to the treatment of severe keratitis associated with DED1.
CyclASol® consists of cyclosporine solubilized in a novel water-free excipient, perfluorobutylpentane, and is the first available solution developed with the water-insoluble cyclosporine. This water-free drug product does not require preservatives, oils or surfactants, which can be irritating and disturb the tear film. The superior tolerability of CyclASol® has been proven clinically.
“I see many patients in my practice whose lives are impacted by dry eye disease. New approved drug therapies for these patients in Europe are very welcome.” said Christophe Baudouin, MD, PhD, FARVO, Professor of Ophthalmology at Quinze-Vingts National Ophthalmology Hospital and President of the European Dry Eye Society “Having a comfortable product that provides clinically meaningful improvements of the ocular surface as early as 2 weeks is addressing an important medical need and could help to limit steroid use."
CyclASol® has demonstrated in two independent adequate and well-controlled, multicenter studies (ESSENCE-12 and ESSENCE-2) clinically meaningful and statistically significant improvements in moderate to severe patients affected by the disease indication. Effects on the ocular surface include a statistically significant reduction in total corneal fluorescein staining score favoring CyclASol® as early as on Day 15. Up to 71.6% of patients responded within four weeks with a clinically meaningful improvement in total corneal staining. This proportion of responders was significantly higher compared to vehicle-treated patients in both studies. Patients responding also showed statistically significant improvements in a variety of symptoms compared to non-responders within 4 weeks. CyclASol® has a favorable tolerability profile demonstrating high patient acceptance and an improved side effect profile. Continued improvement under therapy in both, signs and symptoms of DED, has been clinically demonstrated over a period of up to 56 weeks also confirming the favorable tolerability profile.
“CyclASol® was specifically developed as a potent and comfortable anti-inflammatory dry eye drug therapy with rapid onset of effect for dry eye patients not adequately responding to artificial tears”, said Christian Roesky, Ph.D., CEO, Novaliq. “We are excited by the response of the European Medicines Agency and look forward to hopefully bring CyclASol® to patients in Europe, and ultimately address an unmet medical need for those suffering with dry eye disease.”
In the United States the Food and Drug Administration (FDA) has set a Prescription Drug User Fee Act (PDUFA) target action date for the CyclASol® New Drug Application (NDA) on June 8, 2023.
About Novaliq
Novaliq is a private biopharmaceutical company focusing on the development and commercialization of first- and best-in-class ocular therapeutics based on EyeSol®, the worldwide first water-free technology. EyeSol® is Novaliq’s proprietary water-free technology using ultrapure semifluorinated alkanes (SFAs) that are physically, chemically, and physiologically inert with excellent biocompatibility and a very good safety profile. Two EyeSol® dry eye drug products are in regulatory review by U.S. FDA: CyclASol® and NOV03 (perfluorohexyloctane) with PDUFA target action dates on June 8 and 28, 2023 respectively. In the EU perfluorohexyloctane is registered as a medical device to treat patients with dry eye disease since 2013. The company continues to progress into other ophthalmic indications based on its validated EyeSol® platform.
Novaliq GmbH is headquartered in Heidelberg, Germany and Novaliq Inc. has an office in Cambridge, MA, USA. The long-term shareholder is dievini Hopp BioTech holding GmbH & Co. KG, an active investor in Life and Health Sciences companies. More on www.novaliq.com.
Recommended Readings
- Global Data. Dry Eye Syndrome: Seven-Market Drug Forecast and Market Analysis Update | December 2022
- Sheppard et al. A Water-free 0.1% Cyclosporine A Solution for Treatment of Dry Eye Disease: Results of the Randomized Phase 2B/3 ESSENCE Study. Cornea. 2021 Oct 1;40(10):1290-1297
Any product/brand names and/or logos are trademarks of the respective owners.
© 2023 Novaliq GmbH, Heidelberg, Germany.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230208005056/en/
Contact information
Novaliq Media Contact:
Simone Angstmann-Mehr
info@novaliq.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Perma-Pipe Accelerates Growth with New U.S. Northeast Facility Investment to serve Artificial Intelligence Data Center customers, Provides Middle East Operations’ Update and Concludes the Board’s Review of Strategic Alternatives19.3.2026 15:00:00 EET | Press release
Perma-Pipe International Holdings, Inc. (the “Company”) today announced a strategic expansion initiative focused on accelerating growth through entry into the high-demand U.S. Northeast region. The Company is positioning itself to capitalize on the rapidly expanding Artificial Intelligence (“AI”)-driven data center market in both the United States and international markets while continuing to reinforce its leadership in critical infrastructure solutions. As part of this growth strategy, Perma-Pipe will prioritize investments aimed at expanding its presence in the rapidly evolving AI data center sector. The initiative reflects the Company’s long-term commitment to supporting next-generation technology infrastructure and strengthening its position in the global energy, industrial, and infrastructure markets. Expansion in the U.S. Northeast President & Chief Executive Officer, Saleh Sagr said, “We are excited to announce the expansion of our operations with a new facility in the Northeast
Armis Launches First-of-Its-Kind Benchmark Report Warning of Critical Security Gaps in AI-Native Development19.3.2026 14:00:00 EET | Press release
Armis, the cyber exposure management & security company, is warning that the rapid enterprise adoption of AI-native development is outpacing critical security safeguards, leaving organizations exposed to systemic vulnerabilities. New research from Armis Labs’ Trusted Vibing Benchmark Report, which evaluates 18 leading generative AI models across 31 test scenarios, reveals a 100% failure rate in generating secure code. These vulnerabilities are most prevalent in high-risk areas like memory buffer overflows, design file uploads and authentication systems. Therefore, organizations should immediately implement AI-native application security controls to reduce risk. “The era of vibe coding is here, but speed should not come at the cost of security,” said Nadir Izrael, CTO and Co-Founder of Armis. “Our research finds that the worst offenders are the same ones selling security solutions for the very vulnerabilities their models create. If the industry continues to integrate autonomous code wi
Morocco’s FRMF Welcomes CAF Appeal Board as Upholding Rules, Stability of International Competitions19.3.2026 13:53:00 EET | Press release
Following the announcement by the CAF Appeal Board, the Royal Moroccan Football Federation (FRMF) welcomes the decision, which reaffirms the primacy of competition regulations and reinforces the conditions necessary for the proper conduct of international tournaments. From the outset, following the incidents that led to the interruption of the match, the FRMF maintained a clear and consistent position: the strict application of the governing regulations. The Federation’s approach was solely guided by this principle. Following its appeal, CAF has now confirmed that the applicable regulations were not properly enforced. Throughout the process, the FRMF acted in full compliance with all relevant legal and procedural frameworks, with a constant focus on upholding its rights and preserving the integrity of the competition. This decision provides clarity on the applicable framework and strengthens the consistency and credibility of international competitions, particularly within African foot
Keenfolks Launches KEENFOLKS X_19.3.2026 13:00:00 EET | Press release
The traditional holding company model that has shaped global marketing for decades is facing increasing pressure as capital markets, consolidation activity, and client demands point to a need for structural change. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260319751842/en/ Miguel Machado, CEO and Co-Founder, Keenfolks The marketing industry is searching for a new model. The question is no longer whether agencies need to change, but which ones were built for this shift from the start. Keenfolks, the Integrative AI® partner built natively for the Age of Intelligence, today announces the launch of KEENFOLKS X_ — a new global AI-native marketing network designed to help organizations move beyond fragmented services and toward intelligent systems, scalable solutions, and measurable transformation. The network is built on K OS_, Keenfolks’ proprietary marketing operating system, which connects intelligence, data, automation,
Hilton Announces Exclusive Agreement with YOTEL to Expand Global Footprint in Lifestyle Segment19.3.2026 13:00:00 EET | Press release
Hilton (NYSE: HLT) today announced an exclusive agreement with YOTEL that will provide guests yet another way to stay within the hospitality leader’s growing global portfolio. With highly efficient hotels in urban markets, YOTEL has pioneered ways to meet changing guest needs through stays that feature smart room design, and clever tech-enabled features. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260318705963/en/ YOTEL Boston The franchise agreement with YOTEL expands Hilton’s network, filling a distinct customer need in the growing lifestyle segment in a manner consistent with its proven asset-light model. YOTEL will continue to independently manage and license its brand at 23 hotels across 10 countries, with a goal of more than tripling its portfolio in the coming years. YOTEL will be the first brand in the newly established Select by Hilton. Select by Hilton is designed to grow into a brand that creates new ways to st
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom